NCCN Pharmacy Updates: New Targets in Breast Cancer Therapy
Triple-negative breast cancer continues to be labeled with a poor prognosis secondary to the fact that it tends to be more aggressive and poses a greater risk of recurrence. Because it lacks the receptors that many drugs have been designed to target, the standard of practices remains chemotherapy. Therefore, research has been focused on trying to identify other therapeutic targets for which we already have agents or are currently developing agents.
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Breast Cancer
Staying up-to-date with the available treatment options is important for health care professionals to integrate new evidence-based data into their clinical practice, and being familiar with the toxicity profile is important to optimize patient outcomes.
Management of Metastatic Breast Cancer
The decision-making process for metastatic breast cancer involves a detailed discussion with patients of the benefits and risks associated with all possible treatment strategies. With expanding treatment options, clinicians need to understand important criteria used in picking optimal first-and subsequent line therapies for individuals with metastatic breast cancer and also have a knowledge of the biomarkers that should be tested to guide therapeutic decisions in patients with metastatic breast cancer. 
Locoregional Management of Early-Stage Breast Cancer

Locoregional management strategies have considerably evolved.

Current Insights: Evolving Principles and Controversies of Cancer Risk Assessment and Management of Hereditary Cancers

There is currently a lack of evidence regarding proper procedures and risk management strategies that should follow multi-gene testing, especially when pathogenic or likely pathogenic variants are found for moderate-penetrance genes and when a variant of unknown significance (VUS) is found.

Management of Toxicities with Targeted Therapies for Breast Cancer
Staying up-to-date with the available treatment options is important to clinicians integrating new evidence-based data into their clinical practice, and being familiar with their toxicity profiles is important to optimize patient outcomes.
Management of Metastatic Breast Cancer, Including SABCS Updates
The decision-making process for metastatic breast cancer should involve a detailed discussion with patients of the benefits and risks associated with all possible treatment strategies.
Biomarker Assays for Treatment Selection of Advanced Breast Cancer

Biomarkers identify patients who are likely to respond to a given therapy. These assays and their interpretation can present challenges for clinicians.

Management of Rare Breast Cancers

The management of rare breast cancer subtypes represents a challenge in clinical practice.

Principles of Breast Reconstruction after Surgery

All women undergoing breast cancer treatment should be educated about breast reconstructive options as adapted to their individual clinical situation and be offered an opportunity to consult with a reconstructive plastic surgeon. Coordinating consultation and surgical treatment with a reconstruct

Pages

Subscribe to RSS - Breast Cancer